Welcome to our dedicated page for Curis news (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis stock.
Curis, Inc. (NASDAQ: CRIS) is a biotechnology company that publicly describes its focus as the development of emavusertib (CA-4948), an orally available small molecule inhibitor of IRAK4 and, in some disclosures, FLT3. The Curis news stream highlights clinical progress, financing events, and corporate updates that shape the company’s development plans and capital position.
News about Curis frequently covers clinical data and study milestones for emavusertib. The company has reported interim results from its frontline AML triplet study (emavusertib with venetoclax and azacitidine), updates from the TakeAim Lymphoma and TakeAim Leukemia Phase 1/2 trials in PCNSL, AML and high-risk MDS, and presentations at major medical meetings such as the American Society of Hematology (ASH), the Society for Neuro-Oncology (SNO), and ASCO. These releases often describe response measures such as minimal residual disease status and safety observations within defined patient cohorts.
Investors following CRIS news will also see financing and capital markets announcements, including registered direct offerings, concurrent private placements of pre-funded and common warrants, and a PIPE financing involving Series B convertible preferred stock and multiple warrant series. Curis’s news has detailed the structure of these transactions, the gross proceeds, and the stated use of funds for research and development, general corporate purposes, and working capital.
Additional news items address corporate and regulatory developments, such as business updates, quarterly financial results, inducement equity grants, conference participation, and Nasdaq listing compliance notices related to market value of listed securities requirements. For readers tracking Curis, the CRIS news page provides an organized view of these clinical, financial, and listing-related disclosures in one place, allowing users to review how trial data, capital raises, and regulatory interactions evolve over time.
Curis, Inc. (NASDAQ: CRIS) announced that CEO James Dentzer will present a company overview at the H.C. Wainwright & Co. Global Life Sciences Conference on March 9, 2021. A pre-recorded presentation will be accessible starting at 7:00 am ET. The presentation will be available on-demand on Curis's website under 'Events & Presentations' for about 90 days. Curis specializes in cancer therapeutics, with ongoing trials for treatments targeting various cancers, including non-Hodgkin's lymphoma and acute myeloid leukemia.
Curis, a biotechnology firm specializing in cancer therapeutics, announced that CEO James Dentzer will present at the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, at 1:40 PM ET. A live webcast of the presentation will be accessible on Curis' website, with a replay available for 90 days. Curis is known for its innovative collaborations in immuno-oncology, including exclusive licenses for several small molecule antagonists and kinase inhibitors currently in clinical trials. For further details, visit www.curis.com.
Curis, Inc. (NASDAQ: CRIS) has initiated its Phase 1 trial for CA-4948, a novel IRAK4 kinase inhibitor combined with ibrutinib, targeting relapsed or refractory hematologic malignancies. The trial aims to assess safety, pharmacokinetics, and clinical activity, enrolling approximately 18 patients. Preliminary results from prior studies indicate potential tumor volume reduction with CA-4948. The trial aims to leverage existing clinical sites to expedite progress. However, challenges remain, including the need for further funding and the inherent risks associated with drug development.
Curis, Inc. (CRIS) announced the launch of a Phase 2 trial called LUCAS to evaluate CA-4948, an IRAK4 kinase inhibitor, for anemia treatment in myelodysplastic syndromes (MDS) patients. The trial aims to enroll 84 patients, focusing on efficacy and safety, with recruitment starting in Q2 2021. Positive preliminary data from previous studies supports exploring CA-4948 for lower-risk MDS. The initiative involves collaboration with Dr. Uwe Platzbecker, enhancing Curis' clinical efforts in cancer therapeutics.
Curis, Inc. (NASDAQ: CRIS), a biotech firm specializing in cancer therapeutics, announced that CEO James Dentzer will participate in a fireside chat at the B. Riley Securities Virtual Oncology Investor Conference on January 21, 2021, at 11:00 am ET. A live webcast will be available on Curis's website, with a replay accessible for 90 days post-event. Curis collaborates with Aurigene on immuno-oncology and has ongoing trials for oncology treatments including CA-4948 and CI-8993.
On January 4, 2021, Curis (NASDAQ: CRIS) announced the grant of inducement stock options totaling 185,000 shares to three new employees. These options have an exercise price based on the company's closing stock price on the same day and a vesting period over four years. Each option vests 25% after the first year, followed by 6.25% every three months. This grant was made to incentivize new hires as part of the company's strategy to enhance its talent pool in the competitive biotechnology sector.
Curis, Inc. (NASDAQ: CRIS) has announced that CEO James Dentzer will present at the H.C. Wainwright & Co. Bioconnect 2021 Virtual Conference. The presentation will be available for on-demand viewing starting January 11, 2021, at 6:00 am ET. A live webcast can be accessed on the company's website under "Events & Presentations". Curis focuses on developing cancer therapeutics, with current collaborations on innovative treatments including CA-4948 and CI-8993, both in clinical trials. For more details, visit www.curis.com.
Curis, Inc. (NASDAQ: CRIS) has concluded its public offering of 29.5 million shares at $5.75 each, raising approximately $159.1 million in net proceeds. The offering included an option for underwriters to purchase an additional 3.8 million shares. Funds will be used to advance the development of cancer therapeutics CA-4948 and CI-8993, and to support general working capital until 2023. The offering was executed under a previously filed registration statement with the SEC.
Curis, Inc. (NASDAQ:CRIS) announced the pricing of a public offering of 25,652,174 shares at $5.75 per share, totaling approximately $147.5 million in gross proceeds. The offering is expected to close around December 11, 2020, pending customary conditions. Proceeds will be used for the development of CA-4948 and CI-8893, along with general working capital. The offering is made under a shelf registration statement and involves underwriters such as Cantor Fitzgerald & Co. and JonesTrading Institutional Services.
Curis, Inc. (NASDAQ: CRIS), a biotechnology firm focused on cancer therapeutics, has announced a proposed public offering of its common stock under an existing shelf registration statement. The company plans to grant underwriters a 30-day option to purchase additional shares, up to 15% of the offering size. Proceeds will fund the development of CA-4948 and CI-8993, while also supporting general working capital. Cantor Fitzgerald & Co. and JonesTrading are the joint lead book runners for this offering.